Jagsonpal Pharmaceuticals Ltd
Jagsonpal Pharmaceuticals Q2 Results 2026 (FY27) investor presentation: Revenue & Margins
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
Jagsonpal Pharmaceuticals Ltd Q2 FY27 key numbers
- Revenue
- Q2FY27 consolidated revenue: ₹964 Mn, up 29% YoY.
As stated in Jagsonpal Pharmaceuticals Ltd's Q2 FY27 investor presentation · published 28 Oct 2026. Reported figures, not investment advice.
Based on Jagsonpal Pharmaceuticals Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q2FY27 consolidated revenue: ₹964 Mn, up 29% YoY - Q2FY27 standalone revenue: ₹814 Mn, up 9.3% YoY - H1FY27 standalone revenue: ₹1,636 Mn, up 9.0% YoY - MR (medical rep) productivity improved by Quarter (Q2FY27) Financials (Standalone): - Revenue: ₹814 Mn, up 9.3% YoY - EBITDA: ₹185 Mn, margin 22.7% (2.5% increase YoY) - PAT: ₹126 Mn, margin 15.5% (flat YoY) - Quarter (Q2FY27) Financials (Consolidated): - Revenue: ₹964 Mn, up 29% YoY - EBITDA: ₹186 Mn, margin 19.3% - PAT: ₹123 Mn, margin 12.8% - Outlook:
From Jagsonpal Pharmaceuticals Ltd's Q2 FY27 earnings-call transcript · updated 28 Oct 2026.
Revenue & Sales Performance
- Q2FY27 consolidated revenue: ₹964 Mn, up 29% YoY
- Q2FY27 standalone revenue: ₹814 Mn, up 9.3% YoY
- H1FY27 standalone revenue: ₹1,636 Mn, up 9.0% YoY
- MR (medical rep) productivity improved by 10% YoY
- Revenue growth driven by organic momentum and inorganic acquisitions (Aequitas, Wellness portfolio)
- Explicit outlook: Quarterly revenues expected to cross ₹1,000 Mn in Q3 FY27
- Mission 2028 revenue target: ₹5,000 Mn annually
2 more points from Jagsonpal Pharmaceuticals Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
- Quarter (Q2FY27) Financials (Standalone):
- Revenue: ₹814 Mn, up 9.3% YoY
- EBITDA: ₹185 Mn, margin 22.7% (2.5% increase YoY)
- PAT: ₹126 Mn, margin 15.5% (flat YoY)
- Quarter (Q2FY27) Financials (Consolidated):
- Revenue: ₹964 Mn, up 29% YoY
- EBITDA: ₹186 Mn, margin 19.3%
- PAT: ₹123 Mn, margin 12.8%
2 more points from Jagsonpal Pharmaceuticals Ltd's call on margins
Create a free account to keep reading this call
Capital Expenditure Plans
2 more points from Jagsonpal Pharmaceuticals Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Jagsonpal Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Jagsonpal Pharmaceuticals Ltd — Quarterly revenue & net profit
Q2 FY27 figures are not in this chart yet. Latest shown: Jun 2026 (Q1 FY27). The Q2 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q1 FY27): revenue ₹82 Cr, net profit ₹13 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Jagsonpal Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Sudeep Pharma Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations:** Rs 196.7 crore . Key investor presentation takeaways from Sudeep Pharma Ltd's Q2 FY27 investor presentation — and how it rank
- Zota Health Care Ltd (Q2 FY27)
Revenue from Operations for Q2FY27 is ₹19,933.14 lakhs, up 54.58% YoY from ₹12,894.82 lakhs in Q2FY26. Key investor presentation takeaways from Zota Health Care
- FDC (Q2 FY27)
47,303 lakhs in Q2 September 2025 (approximately 20.9% YoY growth). Key results statement takeaways from FDC Ltd's Q2 FY27 results statement — and how it ranks
- Indoco Remedies Ltd (Q2 FY27)
Consolidated revenues for Q2 FY 2026-27 are ₹5,069 million, up 7.4% year-on-year (YoY) from ₹4,718 million in the same quarter last year. Key results statement
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Jagsonpal Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Jagsonpal Pharmaceuticals Ltd Q2 FY27 results?
Q2FY27 consolidated revenue: ₹964 Mn, up 29% YoY - Q2FY27 standalone revenue: ₹814 Mn, up 9.3% YoY - H1FY27 standalone revenue: ₹1,636 Mn, up 9.0% YoY - MR (medical rep) productivity improved by Quarter (Q2FY27) Financials (Standalone): - Revenue: ₹814 Mn, up 9.3% YoY - EBITDA: ₹185 Mn, margin 22.7% (2.5% increase YoY) - PAT: ₹126 Mn, margin 15.5% (flat YoY) - Quarter (Q2FY27) Financials (Consolidated): - Revenue: ₹964 Mn, up 29% YoY - EBITDA: ₹186 Mn, margin 19.3% - PAT: ₹123 Mn, margin 12.8% - Outlook:
What is Jagsonpal Pharmaceuticals Ltd share price analysis?
Jagsonpal Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 31.3 with a market cap of ₹1,470 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Jagsonpal Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.